Will the FDA approve Galleri at its first multi-cancer screening decision?

Question

This market will resolve YES if the FDA grants premarket approval to GRAIL’s Galleri multi-cancer early detection test in its first substantive decision on the application described in GRAIL’s November 4, 2026 update. Approval must authorise the test for its multi-cancer screening purpose in the United States, potentially with a narrower eligible population, labelling restrictions or post-approval obligations.

The company’s existing laboratory-developed-test availability does not count as FDA a

Problyx · Accepted Answer

Yes — the community forecast puts this at 73%.

Problyx · Answer

No — the community forecast puts this at 27%.